The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Under the deal, Quiver will receive an undisclosed advance payment and research support
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
If approved, DTX401 would be the first treatment to address the disease at its root cause
Subscribe To Our Newsletter & Stay Updated
